PriceTargets.com logo

NASDAQ:REPL - Replimune Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $46.00
  • Forecasted Upside: 131.16 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$19.90 As of 08/9/2022 11:11 AM ET
▼ -0.37 (-1.83%)

This chart shows the closing price for REPL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Replimune Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REPL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REPL

Analyst Price Target is $46.00
▲ +131.16% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $46.00, with a high forecast of $60.00 and a low forecast of $30.00. The average price target represents a 131.16% upside from the last price of $19.90.

This chart shows the closing price for REPL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Replimune Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/15/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/16/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/10/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/11/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/10/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022SVB LeerinkLower Price TargetOutperform$48.00 ➝ $37.00Low
5/24/2022HC WainwrightReiterated RatingBuy$60.00High
5/24/2022WedbushLower Price TargetOutperform$59.00 ➝ $52.00Low
5/20/2022SVB LeerinkLower Price TargetOutperform$49.00 ➝ $48.00High
5/19/2022Piper SandlerLower Price Target$52.00 ➝ $44.00Medium
4/4/2022JPMorgan Chase & Co.Lower Price TargetOverweight$47.00 ➝ $39.00High
3/18/2022BMO Capital MarketsLower Price TargetOutperform$51.00 ➝ $30.00High
1/11/2022HC WainwrightReiterated RatingBuy$60.00Low
11/19/2021Piper SandlerInitiated CoverageOverweight$52.00High
11/15/2021HC WainwrightReiterated RatingBuy$59.00Medium
10/15/2021BTIG ResearchInitiated CoverageBuy$60.00High
8/23/2021SVB LeerinkLower Price TargetOutperform$55.00 ➝ $49.00High
8/9/2021HC WainwrightReiterated RatingBuy$60.00Low
8/9/2021SVB LeerinkLower Price TargetOutperform$56.00 ➝ $55.00Medium
2/5/2021HC WainwrightBoost Price TargetBuy$58.00 ➝ $60.00Medium
2/4/2021SVB LeerinkLower Price TargetOutperform$57.00 ➝ $56.00Medium
11/17/2020BTIG ResearchInitiated CoverageBuy$60.00High
11/10/2020HC WainwrightBoost Price TargetBuy$54.00 ➝ $58.00Low
11/6/2020BMO Capital MarketsBoost Price TargetOutperform$51.00 ➝ $57.00High
11/2/2020Jefferies Financial GroupInitiated CoverageBuy$67.00High
10/15/2020BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$40.00 ➝ $51.00High
10/15/2020BarclaysBoost Price TargetOverweight$29.00 ➝ $50.00High
10/15/2020HC WainwrightUpgradeNeutral ➝ Buy$25.00 ➝ $54.00High
10/15/2020SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $44.00High
10/14/2020Roth CapitalBoost Price TargetBuy$30.00 ➝ $50.00High
10/14/2020Chardan CapitalBoost Price TargetBuy$30.00 ➝ $48.00High
8/7/2020Chardan CapitalReiterated RatingBuy$30.00High
8/7/2020SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $27.00Low
7/1/2020HC WainwrightReiterated RatingBuy ➝ Neutral$25.00High
6/4/2020BMO Capital MarketsBoost Price TargetOutperform$31.00 ➝ $40.00High
6/4/2020HC WainwrightReiterated RatingBuy$24.00 ➝ $25.00High
6/4/2020BarclaysBoost Price TargetOverweight$21.00 ➝ $25.00High
6/4/2020Chardan CapitalReiterated RatingBuy$29.00High
6/3/2020WedbushReiterated RatingOutperformMedium
5/4/2020BarclaysInitiated CoverageOverweight$21.00High
2/13/2020Chardan CapitalReiterated RatingBuy$28.00Low
1/21/2020HC WainwrightReiterated RatingBuy$26.00 ➝ $24.00High
11/20/2019WedbushLower Price TargetOutperform$30.00 ➝ $12.50Medium
11/11/2019Roth CapitalBoost Price TargetBuy$20.00 ➝ $30.00Low
10/24/2019Chardan CapitalReiterated RatingBuy$28.00Low
10/15/2019Chardan CapitalSet Price TargetBuy$28.00High
9/30/2019HC WainwrightReiterated RatingBuy$26.00Low
9/4/2019Roth CapitalInitiated CoverageBuy$20.00High
8/15/2019Chardan CapitalReiterated RatingBuy$28.00Medium
7/23/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$28.00Low
7/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$27.00 ➝ $26.00Low
7/8/2019HC WainwrightInitiated CoverageBuy ➝ Buy$26.00Low
4/24/2019WedbushInitiated CoverageOutperform ➝ Outperform$24.00High
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
8/14/2018SVB LeerinkInitiated CoverageOutperform$25.00Low
8/14/2018BMO Capital MarketsInitiated CoverageOutperform$31.00Low
8/14/2018JPMorgan Chase & Co.Initiated CoverageOverweight$26.00Low
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/11/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/12/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
4/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
6/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2022

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Replimune Group logo
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $19.90
Low: $19.90
High: $20.53

50 Day Range

MA: $18.14
Low: $14.20
High: $21.15

52 Week Range

Now: $19.90
Low: $13.05
High: $35.93

Volume

729 shs

Average Volume

159,929 shs

Market Capitalization

$981.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Replimune Group?

The following Wall Street research analysts have issued research reports on Replimune Group in the last twelve months: BMO Capital Markets, BTIG Research, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, SVB Leerink LLC, and Wedbush.
View the latest analyst ratings for REPL.

What is the current price target for Replimune Group?

7 Wall Street analysts have set twelve-month price targets for Replimune Group in the last year. Their average twelve-month price target is $46.00, suggesting a possible upside of 126.9%. BTIG Research has the highest price target set, predicting REPL will reach $60.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $30.00 for Replimune Group in the next year.
View the latest price targets for REPL.

What is the current consensus analyst rating for Replimune Group?

Replimune Group currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REPL will outperform the market and that investors should add to their positions of Replimune Group.
View the latest ratings for REPL.

What other companies compete with Replimune Group?

Other companies that are similar to Replimune Group include Sorrento Therapeutics, Alector, iTeos Therapeutics, Arcellx and Valneva. Learn More about companies similar to Replimune Group.

How do I contact Replimune Group's investor relations team?

Replimune Group's physical mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company's listed phone number is (781) 222-9600 and its investor relations email address is [email protected] The official website for Replimune Group is www.replimune.com. Learn More about contacing Replimune Group investor relations.